7XP logo

Organon DB:7XP Stock Report

Last Price

€14.99

Market Cap

€3.9b

7D

7.5%

1Y

45.3%

Updated

27 Nov, 2024

Data

Company Financials +

7XP Stock Overview

Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. More details

7XP fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health1/6
Dividends4/6

Organon & Co. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Organon
Historical stock prices
Current Share PriceUS$14.99
52 Week HighUS$20.77
52 Week LowUS$10.11
Beta0.80
11 Month Change-7.67%
3 Month Change-25.39%
1 Year Change45.25%
33 Year Change-40.98%
5 Year Changen/a
Change since IPO-41.28%

Recent News & Updates

Recent updates

Shareholder Returns

7XPDE PharmaceuticalsDE Market
7D7.5%-0.3%0.8%
1Y45.3%-18.3%8.6%

Return vs Industry: 7XP exceeded the German Pharmaceuticals industry which returned -18.3% over the past year.

Return vs Market: 7XP exceeded the German Market which returned 8.6% over the past year.

Price Volatility

Is 7XP's price volatile compared to industry and market?
7XP volatility
7XP Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7XP has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 7XP's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202010,000Kevin Aliwww.organon.com

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.

Organon & Co. Fundamentals Summary

How do Organon's earnings and revenue compare to its market cap?
7XP fundamental statistics
Market cap€3.88b
Earnings (TTM)€1.24b
Revenue (TTM)€6.12b

3.1x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7XP income statement (TTM)
RevenueUS$6.41b
Cost of RevenueUS$2.68b
Gross ProfitUS$3.73b
Other ExpensesUS$2.43b
EarningsUS$1.30b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.05
Gross Margin58.26%
Net Profit Margin20.30%
Debt/Equity Ratio1,774.6%

How did 7XP perform over the long term?

See historical performance and comparison

Dividends

7.1%

Current Dividend Yield

22%

Payout Ratio

Does 7XP pay a reliable dividends?

See 7XP dividend history and benchmarks
When do you need to buy 7XP by to receive an upcoming dividend?
Organon dividend dates
Ex Dividend DateNov 12 2024
Dividend Pay DateDec 12 2024
Days until Ex dividend16 days
Days until Dividend pay date14 days

Does 7XP pay a reliable dividends?

See 7XP dividend history and benchmarks